Utilizing the GPEx® suite of technologies for cell line development and biomanufacturing of difficult-to-express proteins

Register free: ​ https://www.pharmtech.com/pt_w/gpex

Event Overview:

Biopharmaceutical products in development continue to increase in complexity, which poses a challenge for pharmaceutical companies looking to improve speed and efficiency of biologic development. Cell line development is a critical step in the development process that impacts protein quality, manufacturing scalability/efficiency, and timelines. The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines. The GPEx platform is particularly beneficial for complex proteins, such as multi-specific antibodies, unique protein fusions, bioconjugates (including ADCs), proteins requiring cleavage, and proteins requiring other post-translational modification not typically performed by CHO cells. 

Key Learning Objectives:

• Learn about new cell line development methodologies that are enabling these complex programs to be performed more efficiently
• Hear multiple case studies taking complex biopharmaceuticals through the development process
• Understand a new approach to generate stable pooled cell lines, enabling shortened development timelines

Speaker:

Greg Bleck, Ph.D., Vice President, R&D, Biologics

Time and Date:

Tuesday, March 23, 2021, 1pm EDT | 10am PDT | 6pm GMT | 7pm CET

On demand available after final airing until March 23, 2022

Sponsor: Catalent

Register free: https://www.pharmtech.com/pt_w/gpex